Cargando…

Rapid Virological Response Represents the Highest Prediction Factor of Response to Antiviral Treatment in HCV-Related Chronic Hepatitis: a Multicenter Retrospective Study

BACKGROUND: Standard [i.e. pegylated interferon (Peg-IFN) + ribavirin] treatment of hepatitis C virus (HCV)-related chronic hepatitis is associated with a sustained virological response (SVR) in 50 - 90% of patients. A rapid virological response (RVR) (i.e. negative HCV-RNA after 4 weeks of treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Federico, Alessandro, Masarone, Mario, Romano, Marco, Dallio, Marcello, Rosato, Valerio, Persico, Marcello
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Kowsar 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4532787/ https://www.ncbi.nlm.nih.gov/pubmed/26286149 http://dx.doi.org/10.5812/hepatmon.15(6)2015.18640

Ejemplares similares

NAFLD and Extra-Hepatic Comorbidities: Current Evidence on a Multi-Organ Metabolic Syndrome
por: Rosato, Valerio, et al.
Publicado: (2019)

The Role of Fructose in Non-Alcoholic Steatohepatitis: Old Relationship and New Insights
por: Federico, Alessandro, et al.
Publicado: (2021)

The effect of antiviral therapy on hepatitis C virus-related thrombocytopenia: a case report
por: Lebano, Rita, et al.
Publicado: (2014)

Role of Oxidative Stress in Pathophysiology of Nonalcoholic Fatty Liver Disease
por: Masarone, Mario, et al.
Publicado: (2018)

Vascular Endothelial Dysfunction in Inflammatory Bowel Diseases: Pharmacological and Nonpharmacological Targets
por: Gravina, Antonietta Gerarda, et al.
Publicado: (2018)

Corrigendum to “Role of Oxidative Stress in Pathophysiology of Nonalcoholic Fatty Liver Disease”
por: Masarone, Mario, et al.
Publicado: (2021)

PNPLA3, TM6SF2, and MBOAT7 Influence on Nutraceutical Therapy Response for Non-alcoholic Fatty Liver Disease: A Randomized Controlled Trial
por: Dallio, Marcello, et al.
Publicado: (2021)

The Role of Resveratrol in Liver Disease: A Comprehensive Review from In Vitro to Clinical Trials
por: Izzo, Carmine, et al.
Publicado: (2021)

Qualitative and Quantitative Evaluation of Dietary Intake in Patients with Non-Alcoholic Steatohepatitis
por: Federico, Alessandro, et al.
Publicado: (2017)

Liver biopsy in type 2 diabetes mellitus: Steatohepatitis represents the sole feature of liver damage
por: Masarone, Mario, et al.
Publicado: (2017)

Country-Wide HCV Elimination Strategies Need to Reach Older Patients in the General Population: The Italian Experience
por: Torre, Pietro, et al.
Publicado: (2023)

Nutrigenomics and Nutrigenetics in Metabolic- (Dysfunction) Associated Fatty Liver Disease: Novel Insights and Future Perspectives
por: Dallio, Marcello, et al.
Publicado: (2021)

Correction to: “Non alcoholic fatty liver disease and eNOS dysfunction in humans”
por: Persico, Marcello, et al.
Publicado: (2017)

“Non alcoholic fatty liver disease and eNOS dysfunction in humans”
por: Persico, Marcello, et al.
Publicado: (2017)

HCV genotype 1a shows a better virological response to antiviral therapy than HCV genotype 1b
por: Pellicelli, Adriano M, et al.
Publicado: (2012)

The Impact of Antiviral Therapy and the Influence of Metabolic Cofactors on the Outcome of Chronic HCV Infection
por: Persico, Marcello, et al.
Publicado: (2011)

Skin Adverse Events During Dual and Triple Therapy for HCV-Related Cirrhosis
por: Federico, Alessandro, et al.
Publicado: (2014)

The Bisphenol A Induced Oxidative Stress in Non-Alcoholic Fatty Liver Disease Male Patients: A Clinical Strategy to Antagonize the Progression of the Disease
por: Federico, Alessandro, et al.
Publicado: (2020)

Screening for HCV infection combined with SARS-CoV-2 vaccination in the Campania region
por: Torre, Pietro, et al.
Publicado: (2022)

Sustained virological response in HIV/HCV co-infected patients without rapid virological response (RVR) on peginterferon-ribavirin therapy
por: Labarga, P, et al.
Publicado: (2010)

Evaluation of the Effect Derived from Silybin with Vitamin D and Vitamin E Administration on Clinical, Metabolic, Endothelial Dysfunction, Oxidative Stress Parameters, and Serological Worsening Markers in Nonalcoholic Fatty Liver Disease Patients
por: Federico, Alessandro, et al.
Publicado: (2019)

Risk Factors for Liver Decompensation and HCC in HCV-Cirrhotic Patients after DAAs: A Multicenter Prospective Study
por: Morisco, Filomena, et al.
Publicado: (2021)

Rapid virological response of telaprevir and boceprevir in a Brazilian cohort of HCV genotype 1 patients: a multicenter longitudinal study
por: Borba, Helena HL, et al.
Publicado: (2017)

Management of the HBV reactivation in isolated HBcAb positive patients affected with Non Hodgkin Lymphoma
por: Masarone, Mario, et al.
Publicado: (2014)

Coeliac disease and C virus-related chronic hepatitis: a non association
por: Gravina, Antonietta Gerarda, et al.
Publicado: (2012)

Associated screening for HCV and SARS‐Cov2 infection in an urban area of Southern Italy: A cohort study
por: Coppola, Carmine, et al.
Publicado: (2021)

Predicting Hepatocellular Carcinoma Risk in Patients with Chronic HCV Infection and a Sustained Virological Response to Direct-Acting Antivirals
por: D’Ambrosio, Roberta, et al.
Publicado: (2021)

Chemical Effect of Bisphenol A on Non-Alcoholic Fatty Liver Disease
por: Dallio, Marcello, et al.
Publicado: (2019)

Clinical outcomes after treatment with direct antiviral agents: beyond the virological response in patients with previous HCV-related decompensated cirrhosis
por: Pageaux, Georges-Philippe, et al.
Publicado: (2022)

Factors associated with rapid and early virologic response to peginterferon alfa-2a/ribavirin treatment in HCV genotype 1 patients representative of the general chronic hepatitis C population
por: Rodriguez-Torres, M, et al.
Publicado: (2010)

Viral hepatitis: Milestones, unresolved issues, and future goals
por: Torre, Pietro, et al.
Publicado: (2021)

Very rapid virologic response and early HCV response kinetics, as quick measures to compare efficacy and guide a personalized response-guided therapy
por: Yakoot, Mostafa, et al.
Publicado: (2016)

Directly Acting Antiviral-Based Treatment for HCV-Infected Persons Who Inject Drugs: A Multicenter Real-Life Study
por: Messina, Vincenzo, et al.
Publicado: (2020)

Beneficial Effects of Silybin Treatment After Viral Eradication in Patients With HCV-Related Advanced Chronic Liver Disease: A Pilot Study
por: Cossiga, Valentina, et al.
Publicado: (2022)

Silymarin/Silybin and Chronic Liver Disease: A Marriage of Many Years
por: Federico, Alessandro, et al.
Publicado: (2017)

A Patient with HCV Infection and a Sustained Virological Response to Direct-acting Antiviral Treatment Who Developed Inclusion Body Myositis
por: Kuwano, Toru, et al.
Publicado: (2018)

Sustained virological response rates with direct-acting antivirals in black subjects with HCV genotype 1 infection: systematic analysis of clinical trials
por: Struble, Kimberly, et al.
Publicado: (2019)

From Non-Alcoholic Steatohepatitis (NASH) to Hepatocellular Carcinoma (HCC): Epidemiology, Incidence, Predictions, Risk Factors, and Prevention
por: Motta, Benedetta Maria, et al.
Publicado: (2023)

Pegylated interferon-alfa-2a monotherapy in patients infected with HCV genotype 2 and importance of rapid virological response
por: Etoh, Reiko, et al.
Publicado: (2011)

2224. Receipt and Virologic Outcomes of HCV Direct-Acting Antivirals by Alcohol Use and HIV Status
por: Cartwright, Emily J, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_59a5afkbgbon778cvaa6ud2ldb